Full-Time

Head of Treasury

Posted on 5/9/2026

Mallinckrodt

Mallinckrodt

1,001-5,000 employees

Specialty pharmaceutical developer, manufacturer, distributor

Compensation Overview

$330k - $430k/yr

+ Bonus

Bridgewater Township, NJ, USA

In Person

Must live within commuting distance of Bridgewater, NJ; travel less than 50%.

Category
Finance & Banking (1)
Required Skills
Risk Management
Requirements
  • B.S. degree in Business/ Finance, Economics, Accounting or related field is required.
  • Minimum of 12-15 years’ experience including finance and treasury experience with at least 5 years in a leadership role.
  • Proven track record in liquidity management, financing and risk management.
  • Strong knowledge of capital markets, risk management, asset management, capital structure, cash management and treasury systems.
  • Excellent management and leadership skills and demonstrated success in leading, developing and mentoring a group of professionals.
  • Proactive problem solving and decisions making skills.
  • Must be well organized, energetic, highly intelligent, and entrepreneurial.
  • Ability to thrive in a fast-paced, dynamic environment.
  • Ability to interact with many people at a variety of levels within the organization.
  • Strategic thinking with strong verbal, writing and analytical skills.
  • Must have outstanding communication skills.
  • Must be persuasive and goal oriented.
  • High integrity and commitment to corporate governance.
  • Travel up to 50%.
Responsibilities
  • Lead the global cash forecasting and planning process and ensure that the company’s global cash obligations are met in a cost-effective manner.
  • Manage the movement of funds to meet daily operating needs and ensure appropriate internal controls are in place.
  • Provide oversight and coordination of treasury department decisions to ensure conformity with regulatory requirements.
  • Manage global contingency and crisis recovery plans with respect to treasury activities.
  • Evaluate the Company's capital structure.
  • Ensure sufficient financial flexibility is maintained to fund potential growth initiatives and strengthen the company’s capital structure.
  • Advise on optimal borrowing and investment decisions (including the mixture of fixed-rate versus floating-rate debt).
  • Manage the Company’s long- and short-term debt and monitor the markets for opportunities to minimize interest rate risk.
  • Negotiate and manage credit arrangements and maintain good relations with credit rating agencies.
  • Monitor foreign exchange transactions and exposure.
  • Apply value-at-risk analysis.
  • Provide operations with necessary spot foreign exchange funding.
  • Assess value of FX hedging.
  • Provide oversight of Treasury policies and procedures to ensure adequate risk management.
  • Place insurance coverage with appropriate risk retention and competitive premiums.
  • Advise business units on risk reduction actions and business continuity programs.
  • Establish and manage relationships with major commercial banks, investment banks and other external advisors to achieve favorable terms and to create the most effective and productive treasury department.
  • Assess financing ideas that are presented by commercial banks and investment banks and determine appropriate action steps.
  • Provide the professional leadership necessary to build and maintain a “best-in-class” function.
  • Lead by example in areas of change management and be able to think creatively about talent development and organizational structure.
Desired Qualifications
  • M.B.A. is preferred.
  • Professional certifications (e.g. CTP, CFA, etc.) are highly desirable.

Mallinckrodt is a global specialty pharmaceutical company that develops, manufactures, and distributes drugs and therapies for complex and rare conditions, serving healthcare providers, hospitals, and patients mainly in the United States and Europe. Its products target areas such as autoimmune diseases, rare diseases, and critical care, and the business rests on research and development, manufacturing, and sales. The company differentiates itself through a patient-centric approach, a commitment to integrity, ongoing innovation, and collaboration, grounded in more than 150 years of experience and a focus on ESG initiatives. Its goal is to improve the health and well-being of patients worldwide by delivering specialty medicines and advancing sustainable practices.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Hazelwood, Missouri

Founded

1867

Simplify Jobs

Simplify's Take

What believers are saying

  • Merger with Endo completed, forming NYSE-listed therapeutics leader by Q4 2025.
  • Reduced debt 47% to $865.6M and grew Acthar Gel sales 14.2% in 2024.
  • Sold Therakos for $925M, optimizing portfolio for specialty pharmaceuticals.

What critics are saying

  • Endo merger integration disrupts operations, overloading with $6.7B debt.
  • Therakos sale drops immunotherapy revenue, losing edge to Amgen immediately.
  • Acthar Gel's $300K pricing triggers DOJ probe and $500M fines within 18 months.

What makes Mallinckrodt unique

  • Mallinckrodt specializes in Acthar Gel for autoimmune diseases over 150 years.
  • Focuses on rare diseases and critical care therapies for underserved patients.
  • Launched Acthar Gel self-injectable to improve patient adherence and convenience.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Mallinckrodt who can refer or advise you

Benefits

Performance Bonus

Relocation Assistance

Company News

PR Newswire
Nov 10th, 2025
Par Health Completes Spin-Off from Mallinckrodt, Creating an Independent Leader in Generic Pharmaceuticals and Sterile Injectables

Launches as Top 15 U.S. Generic Drug Manufacturer, Largest U.S. Producer of Active Pharmaceutical Ingredients and Premier U.S. Producer of Sterile Injectables...

Contract Pharma
Aug 6th, 2025
Mallinckrodt Names Christiana Stamoulis President and CFO

Mallinckrodt plc appointed Christiana Stamoulis as President and Chief Financial Officer, effective September 22, 2025.

Stock Titan
Aug 1st, 2025
Mallinckrodt-Endo Merger Creates Therapeutics Leader

Mallinckrodt and Endo have completed a merger to form a global therapeutics leader. The companies will combine their generics businesses and Endo's sterile injectables business, which will be spun off as an independent company by Q4 2025. The newly branded company will be listed on the New York Stock Exchange following the spin-off.

The Business Journals
Jul 25th, 2025
Mallinckrodt Reaches $7B Merger Milestone

Mallinckrodt has reached a milestone in a $7 billion merger deal.

Sharecast
Mar 13th, 2025
Mallinckrodt and Endo to merge in $6.7bn deal

Pharmaceutical firm Mallinckrodt said on Thursday that it has agreed to merge with Endo in a $6.7bn deal.